Spravato (Esketamine) Denied by Insurance? How to Appeal

Spravato (esketamine) is an FDA-approved nasal spray for two specific indications: treatment-resistant depression (TRD) in adults, and major depressive disorder (MDD) with acute suicidal ideation or behavior (MDSI) in adults. Given its FDA approval, many patients assume insurance coverage will be straightforward. In practice, Spravato denials are surprisingly common — and surprisingly winnable on appeal.

What Makes Spravato Different From IV Ketamine

Unlike IV ketamine (which is off-label for depression), Spravato has full FDA approval for TRD and MDSI. It is also subject to the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, which requires that:

• Spravato be administered in a certified healthcare facility
• Patients be monitored for at least two hours after administration
• Prescribers and pharmacies be enrolled in the REMS program

The REMS requirements mean Spravato cannot be taken home — it must be administered at a certified clinical site. This contributes to its high cost (typically $800 or more per session) and to insurance administration disputes about facility fees, observation charges, and session bundling.

Common Reasons Insurers Deny Spravato

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denials based on insufficient prior treatment failures. Most Spravato coverage policies require documentation of two or more adequate antidepressant failures. The dispute often centers on what counts as an "adequate" trial — dose, duration, and drug class. Your appeal must document each failed trial with specifics: drug name, dose, duration, and reason for discontinuation (lack of efficacy, not just side effects).

REMS certification disputes. Some insurers deny Spravato claims because the prescribing provider or dispensing pharmacy is not REMS-certified. If you received Spravato at a REMS-certified facility, document that certification explicitly in your appeal.

Facility fee denials. Because Spravato must be administered in a clinical facility, claims often include a facility fee in addition to the drug cost. Insurers may approve the drug but deny the facility fee as a separate charge. Under Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA, facility fees for mental health procedures must be treated comparably to facility fees for comparable medical procedures.

Step therapy to try Spravato before IV ketamine, or vice versa. Some plans require Spravato be tried before approving IV ketamine. Others deny Spravato if IV ketamine has not been tried first. Your appeal should address the specific step therapy requirement and document why the required prior step was tried (or why it is not appropriate).

Maintenance dose denials. The FDA-approved Spravato protocol involves an acute treatment phase (twice weekly for four weeks) followed by a maintenance phase. Some insurers approve the acute phase but deny maintenance dosing. Your psychiatrist must document ongoing medical necessity for maintenance treatment.

MHPAEA Arguments for Spravato Denials

Spravato is a unique case because it is FDA-approved — the "experimental" denial argument that plagues IV ketamine is not available. However, MHPAEA arguments remain relevant:

• If the plan imposes more restrictive step therapy requirements for Spravato than for comparable medical treatments, that is an NQTL violation.
• If facility fees are covered for comparable medical procedures (e.g., observation services after IV infusion for medical conditions) but denied for Spravato sessions, that is a parity violation.
• If prior authorization review for Spravato is more burdensome than for comparable specialty medical drugs, that is an NQTL violation.

Building Your Spravato Appeal

Include in your appeal:

• Documentation of the FDA approval for your specific indication (TRD or MDSI)
• Records of all prior antidepressant trials (names, doses, duration, outcome)
• Treating psychiatrist's letter confirming the TRD or MDSI diagnosis and clinical rationale for Spravato
• REMS program certification documentation for the prescribing facility
• Rebuttal of the specific denial rationale (step therapy, facility fee, maintenance dosing, etc.)
• MHPAEA comparative analysis if step therapy or facility fee parity is at issue

Suicidal Ideation and Expedited Review

If Spravato is sought for MDSI — active suicidal ideation — the situation is clinically urgent. You are entitled to an expedited appeal with a 72-hour response deadline. Document the clinical urgency explicitly in your appeal and request expedited review.

Fight Back With ClaimBack

Spravato denials often hinge on technical documentation — prior treatment history, REMS compliance, facility billing codes. ClaimBack helps you organize and present this documentation in the format insurers require, so your appeal is complete and compelling.

Start your Spravato appeal at ClaimBack today.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?